Secondly, due to the limited sample size, we focused on testing differences between pCR and residual disease and were not able to further investigate these differences when stratifying by ER+ versus ER-neg, HER2+ tumour subtypes specifically. This evidence concerns the gene ERBB2 and neoplasm.